In Vitro: Pretreatment with 50 mM 4-phenylpyridine, reduces IC50 (concentration for 50% inhibition of twitch amplitude) values of MPTP from 53 to 18 mM and d-tubocurarine from 0.7 to 0.3 mM, respectively, in mouse phrenic nerve-diaphragm.
In Vivo: MPTP hydrochloride can be used in animal modeling to build Parkinson's syndrome models.
The toxic effect of MPTP can be completely abolished in vivo by treatment with a monoamine oxidase inhibitor and potentiated by an inhibitor of catechol-O-methyltransferase. Gas1 expressions are significantly elevated in the majority of the reactive astrocytes of the brains with LPS or MPTP insults in animal models.